Neurotech's NT-501 meets in Phase II for macular telangiectasia

Neurotech Pharmaceuticals Inc. (Cumberland, R.I.) reported data from a Phase II trial in 67 patients with macular telangiectasia showing that implanted Renexus (NT-501) met the primary endpoint of reducing progressive loss of photoreceptors from baseline to 24 months as measured by the change in ellipsoid zone using spectral domain optical coherence tomography (sdOCT) vs. sham-treated control eyes (increase in the area of the ellipsoid zone of 0.148 mm² vs. 0.213 mm², p=0.03). On a secondary endpoint, reading speed was maintained in NT-501-treated eyes while deteriorating in sham control eyes (p=0.016). NT-501 also significantly increased macular thickness vs. sham control eyes (p=0.007). NT-501 was generally well tolerated.

Other secondary endpoints in the U.S. and Australian trial include retinal sensitivity and best corrected visual acuity (BCVA)...